drugset
drugset / Trial / NCT04848753

Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

NCT04848753 ↗

Phase 3 Active not recruiting 663 enrolled Shanghai Junshi Bioscience Co., Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

This is a randomized, placebo-controlled, multi-center, double-blinded, Phase III study to determine the efficacy and safety of patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy.

Timeline

Start
2021-05-12
Primary completion
2027-05-12
Completion
2027-05-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Toripalimab Monoclonal antibody — —
Background Cisplatin Other / unclassified — —
Background Paclitaxel Small molecule — —

Indications

esophageal squamous cell carcinoma